Novo Nordisk ( NVO -2.98%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

New York, New York-- (Newsfile Corp. - February 9, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE: NVO) and certain ...

Novo Nordisk is a healthcare company focused on the research, development, manufacturing, and distribution of pharmaceutical products globally. During the relevant period, Novo Nordisk was conducting ...

It is currently utilizing a legal loophole that allows it to sell compounded semaglutide, the molecule behind Wegovy. By contrast, Novo Nordisk is both the developer and seller of Wegovy ...

One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics ( GPCR 0.16%), was a victim of a ...

It is currently utilizing a legal loophole that allows it to sell compounded semaglutide, the molecule behind Wegovy. By contrast, Novo Nordisk is ... a “Double Down” stock recommendation ...

On this news, the price of Novo Nordisk stock declined roughly 18% during the course of the trading day, from a closing price of $103.44 per share on December 19, 2024 to $85.00 per share on ...

It is currently utilizing a legal loophole that allows it to sell compounded semaglutide, the molecule behind Wegovy. By contrast, Novo Nordisk is ... Before you buy stock in Hims & Hers Health ...